My Companies
Notification
Account
Log Out
Back

Strides Sells 80% Of Pivot Path To Ascent Capital For £1,000m


27 June 2026
Strides Pharma Science Ltd.

Strides announced a deal with Ascent Capital to sell a majority stake in subsidiary Pivot Path, realizing ~£1,000m while retaining ~20%. The transaction values Pivot Path at ~£2,300m post-money and includes £500m primary infusion. Pivot Path reported FY26 revenue of £1,447m and EBITDA £169m.


Recent Events

No recent events

No events have occurred recently

Real time WhatsApp alerts using AI.

Get features of

  • Instant Notifications
  • Competitive Advantage
  • Critical Alerts
Signup or Sign in

Company Information